{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T16:01:20Z","timestamp":1781712080424,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2013,12,1]],"date-time":"2013-12-01T00:00:00Z","timestamp":1385856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T00:00:00Z","timestamp":1573516800000},"content-version":"vor","delay-in-days":2172,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1093\/annonc\/mdt292","type":"journal-article","created":{"date-parts":[[2013,8,7]],"date-time":"2013-08-07T02:31:48Z","timestamp":1375842708000},"page":"2943-2952","source":"Crossref","is-referenced-by-count":47,"title":["Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials"],"prefix":"10.1016","volume":"24","author":[{"given":"W.-X.","family":"Qi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.-N.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-J.","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-N.","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdt292_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/nrc2583","article-title":"Beyond chemotherapy: targeted therapies in ovarian cancer","volume":"9","author":"Yap","year":"2009","journal-title":"Nat Rev Cancer"},{"key":"10.1093\/annonc\/mdt292_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1053\/sonc.2002.37263","article-title":"Role of angiogenesis in tumor growth and metastasis","volume":"29","author":"Folkman","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0020","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1146\/annurev.med.49.1.407","article-title":"Angiogenesis and tumor metastasis","volume":"49","author":"Zetter","year":"1998","journal-title":"Annu Rev Med"},{"key":"10.1093\/annonc\/mdt292_bb0025","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt292_bb0030","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","article-title":"Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"379","author":"van der Graaf","year":"2012","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt292_bb0035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt292_bb0045","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdt292_bb0050","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1200\/JCO.2011.35.3524","article-title":"Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma","volume":"30","author":"Nosov","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0055","doi-asserted-by":"crossref","first-page":"2660","DOI":"10.1200\/JCO.2010.32.4145","article-title":"Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer","volume":"29","author":"Kurzrock","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0060","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","article-title":"Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Grothey","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt292_bb0065","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt292_bb0070","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1002\/hep.26120","article-title":"Hemorrhagic events in hepatocellular carcinoma patients treated with anti-angiogenic therapies","volume":"57","author":"Duffy","year":"2012","journal-title":"Hepatology"},{"key":"10.1093\/annonc\/mdt292_bb0075","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/S0049-3848(12)70016-6","article-title":"Side effects of anti-angiogenic drugs","volume":"129","author":"Elice","year":"2012","journal-title":"Thromb Res"},{"key":"10.1093\/annonc\/mdt292_bb0080","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00228-010-0988-x","article-title":"Risk of high-grade bleeding in patients with cancer treated with bevacizumab: a meta-analysis of randomized controlled trials","volume":"67","author":"Hang","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1093\/annonc\/mdt292_bb0085","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000314980","article-title":"Increased risk of serious hemorrhage with bevacizumab in cancer patients: a meta-analysis","volume":"79","author":"Hapani","year":"2010","journal-title":"Oncology"},{"key":"10.1093\/annonc\/mdt292_bb0090","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/S1470-2045(09)70222-0","article-title":"Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials","volume":"10","author":"Je","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0095","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/1535-7163.MCT-07-0193","article-title":"Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity","volume":"6","author":"Kumar","year":"2007","journal-title":"Mol Cancer Ther"},{"key":"10.1093\/annonc\/mdt292_bb0100","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s00408-011-9332-1","article-title":"The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials","volume":"189","author":"Qi","year":"2011","journal-title":"Lung"},{"key":"10.1093\/annonc\/mdt292_bb0105","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/S1470-2045(12)70335-2","article-title":"Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial","volume":"13","author":"Leboulleux","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0110","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1200\/JCO.2010.29.5717","article-title":"Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial","volume":"29","author":"de Boer","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0115","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial","volume":"30","author":"Wells","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0120","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S0140-6736(98)01085-X","article-title":"Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?","volume":"352","author":"Moher","year":"1998","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt292_bb0125","unstructured":"NCI, Cancer Therapy Evaluation Program CTC v 2.0 and common terminology criteria for adverse events criteria V3.0 (CTCAE) Available at http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm (Jan 27 2013, date last accessed)"},{"key":"10.1093\/annonc\/mdt292_bb0130","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1093\/oxfordjournals.aje.a114447","article-title":"A general estimator for the variance of the Mantel-Haenszel odds ratio","volume":"124","author":"Robins","year":"1986","journal-title":"Am J Epidemiol"},{"key":"10.1093\/annonc\/mdt292_bb0135","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/gepi.20048","article-title":"Heterogeneity testing in meta-analysis of genome searches","volume":"28","author":"Zintzaras","year":"2005","journal-title":"Genet Epidemiol"},{"key":"10.1093\/annonc\/mdt292_bb0140","doi-asserted-by":"crossref","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1093\/annonc\/mdt292_bb0145","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1200\/JCO.2011.39.2993","article-title":"Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: a phase III trial","volume":"30","author":"Scagliotti","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0150","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1200\/JCO.2010.28.5981","article-title":"Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer","volume":"29","author":"Natale","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0155","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1470-2045(10)70132-7","article-title":"Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial","volume":"11","author":"Herbst","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0160","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1200\/JCO.2008.18.6015","article-title":"Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study","volume":"27","author":"Natale","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0165","doi-asserted-by":"crossref","first-page":"4270","DOI":"10.1200\/JCO.2006.10.5122","article-title":"Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer","volume":"25","author":"Heymach","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0170","doi-asserted-by":"crossref","first-page":"5407","DOI":"10.1200\/JCO.2008.17.3138","article-title":"Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer","volume":"26","author":"Heymach","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0175","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","article-title":"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study","volume":"30","author":"Bergh","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0180","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10549-010-1066-x","article-title":"Multicenter phase II randomized trial evaluating antiangiogenic therapy with sunitinib as consolidation after objective response to taxane chemotherapy in women with HER2-negative metastatic breast cancer","volume":"123","author":"Wildiers","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt292_bb0185","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-010-0788-0","article-title":"Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer","volume":"121","author":"Barrios","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdt292_bb0190","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.2010.31.2975","article-title":"Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer","volume":"29","author":"Rugo","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0195","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt292_bb0200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1093\/annonc\/mdt292_bb0205","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jhep.2011.12.013","article-title":"Vandetanib in patients with inoperable hepatocellular carcinoma: a phase II, randomized, double-blind, placebo-controlled study","volume":"56","author":"Hsu","year":"2012","journal-title":"J Hepatol"},{"key":"10.1093\/annonc\/mdt292_bb0210","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1001\/jama.2010.1672","article-title":"Doxorubicin plus sorafenib versus doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial","volume":"304","author":"Abou-Alfa","year":"2010","journal-title":"JAMA"},{"key":"10.1093\/annonc\/mdt292_bb0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","article-title":"Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial","volume":"10","author":"Cheng","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0220","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2007.15.7636","article-title":"Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma","volume":"27","author":"Hauschild","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0225","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1200\/JCO.2007.14.8288","article-title":"Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 study group","volume":"26","author":"McDermott","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0230","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","article-title":"Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study","volume":"12","author":"Kindler","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0235","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0140-6736(08)60661-3","article-title":"Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study","volume":"371","author":"Spano","year":"2008","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt292_bb0240","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"key":"10.1093\/annonc\/mdt292_bb0245","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1200\/JCO.2007.12.3083","article-title":"Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20","volume":"25","author":"Arnold","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdt292_bb0250","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Sherwood","year":"1971","journal-title":"New England Journal of Medicine"},{"key":"10.1093\/annonc\/mdt292_bb0255","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/nm0195-27","article-title":"Angiogenesis in cancer, vascular, rheumatoid and other disease","volume":"1","author":"Folkman","year":"1995","journal-title":"Nature medicine"},{"key":"10.1093\/annonc\/mdt292_bb0260","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1001\/jama.299.8.914","article-title":"Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia","volume":"299","author":"Bennett","year":"2008","journal-title":"JAMA"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367195?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419367195?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/24\/12\/2943\/16701834\/mdt292.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:30:52Z","timestamp":1624519852000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419367195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["S0923753419367195"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdt292","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2013,12]]}}}